Changes in Abdominal Adiposity and Associations With Metabolic Health Markers Following Tirzepatide in Japanese Participants With Obesity Disease: Results From the SURMOUNT-J Study.
Tirzepatide weight loss correlates with deep belly fat reduction and better metabolic health in Japanese patients with obesity.
Phase 3 SURMOUNT-J analysis (n=225) demonstrates that tirzepatide-induced weight loss in Japanese patients with obesity is strongly correlated with visceral adipose tissue reduction (r=0.72–0.84), accompanied by significant improvements in adiponectin, leptin, inflammation markers, and glucose metabolism. Anthropometric measures track closely with VAT changes, supporting their use as VAT surrogates in Japanese clinical practice.
What the study was
- Study design
- Prespecified and post hoc analysis of Phase 3 RCT (SURMOUNT-J)
- Population
- Japanese adults with obesity without diabetes (n=225, tirzepatide 10/15 mg vs placebo)
- Sample size
- 225
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Endocrine Practice
Why it surfaced
Phase 3 RCT sub-analysis; tirzepatide VAT reduction correlated strongly with metabolic improvements in Japanese patients; fills ethnic-specific evidence gap for GLP-1/GIP dual agonist; practical implications for Asian obesity management.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.